目的:分析探讨采用大剂量ARB(缬沙坦320mg)和常规剂量ARB(缬沙坦160mg)治疗心力衰竭的临床疗效,并比较其临床安全性及不良反应发生率。方法:回顾性分析本院收治的100例心力衰竭患者(NYHAⅢ-Ⅳ,EF<40%),将其随机分为对照组(常规剂量ARB)和试验组(大剂量ARB),每组各50例。分析比较两组患者的临床治疗结果,以及临床安全性和不良反应发生率。结果:两组患者的死亡率相比有显著性差异(P<0.05);两组患者的不良反应主要表现为低血压,试验组患者的临床不良反应发生率显著高于对照组患者,具有统计学意义(P<0.05)。结论:大剂量ARB显著降低了心力衰竭患者所有原因的死亡率,其安全性良好,但是使用过程中应注意低血压的发生。 Objective: To investigate the clinical efficacy of high dose ARB (valsartan 320 mg) and conventional ARB (valsartan 160 mg) in the treatment of heart failure and to compare its clinical safety and incidence of adverse reactions. Methods: A total of 100 patients with heart failure (NYHAⅢ-Ⅳ, EF <40%) admitted to our hospital were retrospectively analyzed. They were randomly divided into control group (conventional dose ARB) and experimental group (high dose ARB) example. Analysis of two groups of patients with clinical treatment, as well as clinical safety and adverse reaction rates. Results: There was a significant difference in mortality between the two groups (P <0.05). The adverse reactions of the two groups were mainly hypotension. The incidence of clinical adverse reactions in the experimental group was significantly higher than that in the control group Significance (P <0.05). Conclusion: High-dose ARB significantly reduces the mortality of all causes of heart failure patients, its safety is good, but should pay attention to the occurrence of hypotension during use.